Panelists discuss how emerging intrathecal gene therapy for older patients with spinal muscular atrophy (SMA) shows modest efficacy with fewer systemic adverse effects than intravenous administration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback